Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AML2004: OSHO Arm vs Standard Arm in Elderly AML
NCT01497002Phase 3Completed
- Sponsor
- Leipzig University
- Start
- Apr 2005
- Primary completion
- Jul 2018
- Modality
- Lipid-based Nanoparticles, CAR-T Cells, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of cytarabine, mitoxantrone hydrochloride liposome injection + fludarabine + CD19 CAR-T cells in acute myeloid leukemia (AML), sponsored by Leipzig University. Started Apr 2005; status: completed.
02
Drugs
cytarabinemitoxantrone hydrochloride liposome injection + fludarabine + CD19 CAR-T cells
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT01497002.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01497002.